Combinations being explored include cetuximab plus MRTX849, pembrolizumab, and afatinib in the treatment of KRAS G12C-mutant pancreatic cancer (NCT03785249), as well as cetuximab plus trastuzumab and SNK01 for the treatment of advanced, EGFR-positive pancreatic cancer (NCT04464967). Here, KRAS is linked to familial pancreatic carcinoma.